Welcome to Bracy Analytics, Inc.

Bracy Analytics has collaborated on many  studies and take great pride in our research efforts.

Featured Publication

Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data

Henry Rolka 1 *, Dwayne Bracy 2, Channing Russell 3, David Fram 3, Robert Ball 4

1Centers for Disease Control and Prevention (CDC), Epidemiology Program Office, Division of Public Health Surveillance and Informatics,
2DynTel Corporation
3Lincoln Technologies, Inc.
4Food and Drug Administration (FDA), Center for Biologics Evaluation and Research

E-mail: Henry Rolka (hrolka@cdc.gov)
*Correspondence to Henry Rolka, Centers for Disease Control and Prevention (CDC), National Center for Public Health Informatics (NCPHI), Mailstop E06, Clifton Road, NE, Atlanta, GA 30333, U.S.A.
This article is a U.S. Government work and is in the public domain in the U.S.A.

Funded by:
 Data management Division of the National Immunization Program

ABSTRACT
The objective of the work described in this paper is to develop a means for characterizing the validity of an empirical methodology for detecting signals potentially related to complicated adverse event (AE) coding terms in multidimensional public health surveillance data. The signal detection tool under evaluation is the multi-item gamma Poisson shrinkage (MGPS) estimation program. We were interested in its potential application to passive surveillance system monitoring, to screen for signals of complicated adverse event coding terms (AE terms) in complex and noisy data. The research was to design and produce a flexible and user-friendly utility for probabilistically defining complicated signals in a database, iterating large numbers of applications of the MGPS detection algorithm and establishing proportions of correct detection events. We sought to establish the specificity of the MGPS by developing a random background using a gradient that ranged from rigorous (but not very relevant) to relevant (but noisy).

To establish the sensitivity, signals were defined based on recognized public health issues of interest (such as the introduction of a new vaccine into the population). Methods of representing a signal included a simple pair-wise association consisting of a new vaccine and one AE term, as well as a more realistic complex of multiple AE terms comprising a syndrome. A web application has been developed to create and insert signals with user-defined probabilities in multiple iterations of simulated random background data. Three forms of simulated data based on the vaccine adverse event reporting system (VAERS) cumulative spontaneous database were defined to serve as background noise against which to contrast introduced vaccine adverse event signals: (1) completely random associations between vaccines and AE terms, (2) random associations of vaccine sets and AE term sets preserving naturally observed vaccine co-occurrences and AE term co-occurrences and (3) samples from the actual VAERS data as reported. Rates of detection by the MGPS algorithm can be established for specific signal patterns at varying probabilistic intensities in a choice of random background data forms. Knowing these rates is important for determining the degree of response to an MGPS signal detection event in live data. Published in 2005 by John Wiley & Sons, Ltd.

(p 551-562) Statistics in Medicine 2005 Feb 28;24(4).

Read More

Past Contributions

• Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, and Barlogie B. Autotransplants in multiple myeloma: what have we learned? Blood 88: 838-847.

• Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, and Sawyer JR. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86: 4250-4256.

• Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, and Tricot G. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. JCO Apr 1 1998: 1547-1553.

• Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, and Barlogie B. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. JCO Jul 1 19997: 2659-2666.

• Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clinical Cancer Res. 1996 Jun;2(6):947-52.

• Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, Tricot G, Alexanian R. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant. 1998 Jun;21(11):1101-7.

• Desikan KR, Jagannath S, Siegel D, Nelson J, Bracy D, Barlogie B, Tricot G. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma. Leukemia & Lymphoma. 1998 Feb;28(5-6):501-8.

• Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, Bracy D, Jones R, Crowley J, Tricot G, Barlogie B. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997 Sep;20(6):445-50.

• Guba SC, Vesole DH, Jagannath S, Bracy D, Barlogie B, Tricot G. Peripheral stem cell mobilization and engraftment in patients over age 60. Bone marrow Transplant. 1997 Jul;20(1):1-3.

• Tricot G, Jagannath S, Vesole DH, Bracy D, Desikan KR, Siegel D, Barlogie B. Hematopoietic stem cell transplants for multiple myeloma. Leukemia & Lymphoma;1996 Jun: 22(1-2):25-36.

• Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, Munshi N, Bracy D, Barlogie B, and Butch AW. Oligoclonal Protein Bands and Ig Isotype Switching in Multiple Myeloma Treated With High-Dose Therapy and Hematopoietic Cell Transplantation. Blood 91: 3518-3523.

• Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson b, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, and Tricot G. Superiority of Tandem Autologous Transplantation over Standard Therapy for Previously Untreated Multiple Myeloma. Blood 89: 789-793.

Bracy Analytics Incorporated
3055 Wayward Drive
Marietta, Georgia 30066
Telephone: (770) 509-8994
Fax: (770) 509-8442
Email: info@bracy-analytics.com


Home About UsServicesProjectsPublicationsCareersContact Us
Copyright © 2008 Bracy-Analytics, Inc. | Website maintained by Welden Web Works, LLC